Connor, Clark & Lunn Investment Management (CC&L)
NPCE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Neuropace NPCE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$747K Sell
56,834
-1,425
-2% -$21.4K ﹤0.01% 1222
2025
Q4 		$900K Buy
+58,259
New +$779K ﹤0.01% 1171

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NPCE Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Neuropace (NPCE) stake by 2.4% in Q1 2026, selling an estimated $21.4K and leaving 56,834 shares worth $747K. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NPCE in Q4 2025 and has held it in 2 quarters since. The position peaked at $900K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 56,834 shares of Neuropace worth $747K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,425 Neuropace shares in Q1 2026, an estimated $21.4K.
  • Neuropace made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1222 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Neuropace in Q4 2025 and has held it in 2 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Neuropace position peaked at $900K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.